Cough | Comparison Between Oxomemazine, Guaifenesin and Potassium Iodate Versus Guaifenesin Monotherapy in Acute Cough Treatment
Cough research study
What is the primary objective of this study?
The purpose of this study is evaluate if efficacy of a combination dose of oxomemazine, guaifenesin and potassium iodate is superior than guaifenesin monotherapy in acute cough treatment.
Who is eligible to participate?
Inclusion Criteria: 1. Patients must be able to understand the study procedures agree to participate and give written consent. 2. Patients with productive cough as result an acute URTI (i.e., cold or flu) or allergic cough in the last 10 day. 3. Cough score superior to 3. Exclusion Criteria: 1. Pregnancy or risk of pregnancy. 2. Lactation. 3. Fever above 38º C. 4. Patients with bacterial infections of the upper respiratory tract. 5. Any pathology or past medical condition that can interfere with this protocol.
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Syrup of oxomemazine, guaifenesin and potassium iodate5ml each 4 hours
Drug:Syrup of guaifenesin5ml each 4 hours
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
DRUG 1Syrup of oxomemazine, guaifenesin and potassium iodate
DRUG 2Syrup of guaifenesin
Start Date: February 2013
Completed Date: September 2013
Phase: Phase 3
Primary Outcome: Reduction/improvement of cough symptoms
Secondary Outcome: Tolerance
Study sponsors, principal investigator, and references
Principal Investigator: Felipe Pinho, MD
Lead Sponsor: EMS